#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Noonan syndrome Endocrine ophthalmopathy Hepatitis D Fms-like tyrosine kinase 3 positive Hereditary motor and sensory neuropathy Amyotrophic lateral sclerosis Cystic fibrosis gastrointestinal disease Colon cancer PIK3CA-activated mutation Phaeochromocytoma Anaplastic thyroid cancer Iron overload Philadelphia positive chronic myeloid leukaemia Neurotrophic keratopathy Myasthenia gravis More trials…

    Learn about Rare Diseases

    Sarcoma – Diagnostics Haemolytic uraemic syndrome – Trials in Disease Glomerulonephritis membranoproliferative – Treatment Mantle cell lymphoma refractory IgA nephropathy – Life with Disease Mucous membrane pemphigoid Rhabdoid tumour – Basic Information Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Basal cell naevus syndrome – Trials in Disease Chordoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Antithymocyte Immunoglobulin Oxytocin Synthetic Io102 Hydrochloride Oms906 Bi 3720931 Atomoxetine Hydrochloride LUNRESERTIB Sotatercept Abc-35B-116 Vilobelimab Vortioxetine Labetalol Hydrochloride Alendronic Acid Riboflavin Sodium Phosphate Lactic Acid Pabinafusp Alfa Cx-044933 Melatonin Vusolimogene Oderparepvec Ursodeoxycholic Acid More therapies…

    Learn about Your Condition

    Erdheim-Chester disease Ovarian cancer metastatic Fatty acid oxidation disorder Lichenoid keratosis Propionic acidaemia Andersen-Tawil syndrome Prolymphocytic leukaemia Graft versus host disease Biliary neoplasm Binge eating Primary biliary cholangitis Prinzmetal angina Haemofiltration External cephalic version Thymic carcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Lyon Sud

Centre Hospitalier Lyon Sud

165 Chemin du Grand Revoyet, 69495 Pierre Bénite, Pierre Benite, 69495, France

Want to learn more about this study or check if you can participate? Contact us.

  • N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

    Recruiting

    3 1
    Investigated Diseases:
    • Metabolic dysfunction-associated liver disease
    Investigated Drugs:
    • Ly3437943 Sodium
    • Tirzepatide
    Austria Belgium Bulgaria Czechia France Germany +9

  • A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastrooesophageal cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • FRUQUINTINIB
    • Tipiracil Hydrochloride
    • Trifluridine
    France Germany Spain

  • Study on Stopping Dupilumab in Patients with Severe Asthma Who Have Been on the Drug for Over 3 Years

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Asthma
    Investigated Drugs:
    • Dupilumab
    France

  • Study on Encorafenib and Cetuximab for Patients with BRAF V600E-Mutated Localized Colon or Upper Rectum Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colon cancer
    • Rectal cancer
    Investigated Drugs:
    • Cetuximab
    • Encorafenib
    France

  • Study of Pembrolizumab with Drug Combination for Patients with Microsatellite Stable Metastatic Colorectal Cancer with High Immune Infiltrate

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Capecitabine
    • Fluorouracil
    France

  • Study on Hyperthermic Intraperitoneal Chemotherapy with Cisplatin for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian epithelial cancer
    Investigated Drugs:
    • Cisplatin
    France

  • Comparison of ruxolitinib versus hydroxycarbamide or interferon alfa as first treatment for high-risk polycythemia vera patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Polycythaemia vera
    Investigated Drugs:
    • Hydroxycarbamide
    • Peginterferon Alfa-2A
    • Ruxolitinib
    France

  • Study of Reduced Cyclophosphamide Dose After Haploidentical Stem Cell Transplantation in Patients with Blood Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Haematological malignancy
    Investigated Drugs:
    • Cyclophosphamide
    France

  • Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Sodium Chloride
    Belgium Estonia Finland France Germany Italy +1

  • Study on the Effectiveness and Safety of OVX836 Vaccine for Preventing Influenza in Healthy Adults Aged 18-59

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Influenza
    Investigated Drugs:
    • INFLUENZA A (H1N1/WSN/1933) NUCLEOPROTEIN FUSED TO C-TERMINAL FRAGMENTS OF TWO AVIAN C4BP ALFA CHAIN SEQUENCES
    • Sodium Chloride
    Belgium Finland France Germany
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!